Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

inotuzumab ozogamicin

- PMLiVE

Single Pfizer/BioNTech dose induces strong immune response to COVID-19

Study finds 99% of people generated a robust immune response against COVID-19 after single vaccine dose

- PMLiVE

Pfizer launches early study of COVID-19 antiviral therapeutic

Therapeutic candidate has demonstrated 'potent' in vivo activity against SARS-CoV-2

- PMLiVE

NICE rejects Keytruda for advanced bladder cancer in final guidance

Treatment had been authorised for use in this indication via the Cancer Drugs Fund in 2018

- PMLiVE

EU announces ‘top-up’ of ten million Pfizer/BioNTech vaccines in Q2

Brings total number of doses of the vaccine to be delivered in Q2 to over 200 million

- PMLiVE

Pfizer/BioNTech could supply three billion doses of COVID-19 vaccine in 2022

J&J reportedly facing vaccine supply issues in the EU

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine neutralises Brazil variant, suggests study

Neutralisation of variant 'roughly equivalent' to original SARS-CoV-2 strain

- PMLiVE

Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA

Children born with SMA type 1 typically have a life expectancy of around two years

- PMLiVE

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

The European Medicines Agency is also reviewing an application for the drug

- PMLiVE

UK study finds Pfizer/BioNTech, AZ/Oxford vaccines reduce severe COVID-19 in older people

Data suggests vaccine is 80% effective at preventing hospitalisations in over-80s

- PMLiVE

FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine

Vaccine can be transported/stored at standard pharmaceutical freezer temperatures

- PMLiVE

Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures

New data shows vaccine can be stored at temperatures of -25°C to -15°C

- PMLiVE

Researchers suggest delaying second dose of Pfizer/BioNTech jab to protect more people

Canada-based researchers Skowronski and De Serres say first dose is ‘highly protective’

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links